scispace - formally typeset
M

Michel A. Duchosal

Researcher at University Hospital of Lausanne

Publications -  103
Citations -  13434

Michel A. Duchosal is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Transplantation & Nicotinamide phosphoribosyltransferase. The author has an hindex of 29, co-authored 93 publications receiving 11647 citations. Previous affiliations of Michel A. Duchosal include Scripps Research Institute & University of Lausanne.

Papers
More filters
Journal ArticleDOI

Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

TL;DR: A sensitive HPLC method has been developed for the assay of imatinib in human plasma, by off-line solid-phase extraction followed by HPLC coupled with UV-Diode Array Detection, and is currently being applied in a clinical study assessing the imatinIB plasma concentration variability in a population of chronic myeloid leukemia- and gastro-intestinal stromal tumor-patients.
Journal ArticleDOI

Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial

TL;DR: This first target concentration intervention trial could not formally demonstrate a benefit of “routine TDM” because of small patient number and surprisingly limited prescriber's adherence to dosage recommendations, but shows first prospective indication for TDM being a useful tool to guide drug dosage and shift decisions.
Journal ArticleDOI

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Daniel J. Klionsky, +2522 more
- 01 Jan 2016 - 
TL;DR: Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; A Frozena, AA; Adachi, H, Adeli, K, Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghis
Journal Article

Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease.

TL;DR: Modifications of the PBL transfer method that minimize transfer time and cellular manipulations are described, leading to a more effective population of SCID mouse recipients and may expand the use of these chimeric mice for the manipulations of human immune cells in vivo.